quinoline; compound with urea | 32315-69-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: quinoline; compound with urea
• 英文别名: Chinolin; Verbindung mit Harnstoff；Quinoline;urea；quinoline;urea
• CAS: 32315-69-8
• 化学式: 3CH₄N₂O*C₉H₇N
• 分子量: 309.328
• InChiKey: RDVKMBOHJLXTTP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.26
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  82
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  quinoline; compound with urea 生成 氨
  参考文献：
  名称：

  Pucher; Dehn, Journal of the American Chemical Society, 1921, vol. 43, p. 1755

  摘要：

  DOI：

文献信息

• Pharmaceutical composition for the use in a combination therapy for prevention or treatment of C-Met or angiogenesis factor induced diseases
  申请人：Samsung Electronics Co., Ltd

  公开号：EP2708556A1

  公开（公告）日：2014-03-19

  Provided is a method of combination therapy for prevention or treatment of c-Met-induced or angiogenesis factor-induced diseases including co-administering an angiogenesis inhibitor and an anti-c-Met antibody or an antigen-binding fragment thereof to a patient.

  本发明提供了一种用于预防或治疗 c-Met 诱导的疾病或血管生成因子诱导的疾病的联合治疗方法，包括向患者联合施用血管生成抑制剂和抗-Met 抗体或其抗原结合片段。
• Factors and cells that provide for induction of bone, bone marrow, and cartilage
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US11083755B2

  公开（公告）日：2021-08-10

  Methods, compositions and kits for producing functional chondrocytes, skeletal cells, bone marrow stromal cells, and progenitor cells thereof are provided. These methods, compositions and kits find use in producing chondrocytes, osteoblasts, stromal cells, and progenitor cells thereof in vivo, or in vitro for transplantation, for experimental evaluation, as a source of lineage- and cell-specific products, and the like, for example for use in treating human disorders of the cartilage, bone and hematopoietic system. In some embodiments, specific combinations of protein factors are identified for reprogramming non-skeletal cells into bones, hematopoietic stroma, and chondrocytes, which may be provided in vitro or in vivo.

  提供了生产功能性软骨细胞、骨骼细胞、骨髓基质细胞及其祖细胞的方法、组合物和试剂盒。这些方法、组合物和试剂盒可用于在体内或体外生产软骨细胞、成骨细胞、基质细胞及其祖细胞，以用于移植、实验评估、作为细胞系和细胞特异性产品的来源等，例如用于治疗人类软骨、骨骼和造血系统疾病。在一些实施方案中，确定了蛋白质因子的特定组合，用于将非骨骼细胞重编程为骨骼、造血基质和软骨细胞，可在体外或体内提供。
• Small molecules and a pharmacophore model for inhibition of anthrax lethal factor
  申请人：Bavari Sina

  公开号：US20050251345A1

  公开（公告）日：2005-11-10

  Disclosed herein is a pharmacophore model for inhibiting anthrax lethal factor protease activity which comprises a first aromatic center A, a second aromatic center B, a first polar center C, a second polar center D, a third polar center E, and a neutral linker F. In some embodiments, the distance between the first aromatic center A and the neutral linker F is about 4.7 to about 6.7 Å, preferably about 5.7 Å. In some embodiments, the distance between the neutral linker F and the second aromatic center B is about 3.4 to about 4.4 Å, preferably about 3.9 Å. In some embodiments, the distance between first aromatic center A and the first polar center C is about 5.5 to about 7.5 Å, preferably about 6.5 Å. In some embodiments, the distance between the first aromatic center A and the second polar center D is about 4.6 to about 6.6 Å, preferably about 5.6 Å. In some embodiments, the distance between the second aromatic center B and the second polar center D is about 3.6 to about 4.6 Å, preferably about 4.1 Å. In some embodiments, the distance between the second aromatic center B and the third polar center E is about 2.6 to about 3.6 Å, preferably about 3.1 Å. In some embodiments, the distance between the first polar center C and the third polar center E is about 15.6 to about 19.6 Å, preferably about 17.6 Å. Also disclosed are small molecules fitting the pharmacophore model and compositions and methods of using thereof.

  本文公开了一种用于抑制炭疽致死因子蛋白酶活性的药理模型，它包括第一芳香中心A、第二芳香中心B、第一极性中心C、第二极性中心D、第三极性中心E和中性连接体F。在一些实施方案中，第一芳香中心A与中性连接体F之间的距离约为4.7至约6.7埃，优选约5.7埃。在一些实施方案中，中性连接体 F 与第二芳香中心 B 之间的距离为约 3.4 Å 至约 4.4 Å，优选约 3.9 Å。在某些实施方案中，第一芳香中心 A 与第一极性中心 C 之间的距离为约 5.5 Å 至约 7.5 Å，优选约 6.5 Å。在一些实施方案中，第一芳香族中心 A 和第二极性中心 D 之间的距离为约 4.6 至约 6.6 Å，优选约 5.6 Å。在一些实施例中，第二芳香中心 B 和第二极性中心 D 之间的距离为约 3.6 至约 4.6 Å，优选约 4.1 Å。在一些实施方案中，第二芳香族中心 B 与第三极性中心 E 之间的距离为约 2.6 至约 3.6 Å，优选约 3.1 Å。在某些实施方案中，第一极性中心 C 和第三极性中心 E 之间的距离为约 15.6 至约 19.6 Å，优选约 17.6 Å。还公开了符合药效模型的小分子及其组合物和使用方法。
• Combinations for the treatment of cancer
  申请人：Chang David

  公开号：US20060216288A1

  公开（公告）日：2006-09-28

  This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer.

  本发明属于药物制剂领域，具体涉及治疗癌症的化合物、组合物、用途和方法。
• COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS
  申请人：Amgen, Inc

  公开号：EP1915151B1

  公开（公告）日：2011-08-17